Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12985789 | 0.82 | SLC6A4 (0.32) | — | |
| SCHEMBL21343306 | 0.81 | NOS3 (0.32) | NOS3NOS1NOS2 | |
| SCHEMBL24876292 | 0.79 | NOS3 (0.31) | NOS3NOS1NOS2 | |
| SCHEMBL11991400 | 0.79 | HRH3 (0.34) | — | |
| SCHEMBL24555490 | 0.78 | CYP2D6 (0.35) | SORT1 | |
| SCHEMBL24398978 | 0.78 | TSHR (0.34) | NOS3NOS1NOS2 | |
| SCHEMBL4546630 | 0.76 | NOS3 (0.36) | NOS3NOS1NOS2 | |
| SCHEMBL4546619 | 0.76 | GBA1 (0.30) | — | |
| SCHEMBL21343583 | 0.76 | — | — | |
| SCHEMBL24555489 | 0.75 | CYP3A4 (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024147972-A2 | DNA POLYMERASE THETA INHIBITORS CONTAINING NON-SATURATED 5-MEMBERED HETEROCYCLIC RINGS AND USE THEREOF | THOMAS JEFFERSON UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024076670-A2 | TETHERED HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024076672-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024076674-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | ESSA PHARMA INC. (CA) | 2023-11-23 | — | — | US | disclosed |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-09 | — | — | US | disclosed |
| WO-2023173083-A1 | TETRAHYDROINDOLE DERIVATIVES AS EGFR AND/OR HER2 INHIBTORS USEFUL FOR THE TREATMENT OF CANCER | SCORPION THERAPEUTICS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-18 | — | — | US | disclosed |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2023-07-04 | — | — | US | disclosed |
| WO-2023283453-A1 | PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF | DICE ALPHA, INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| EP-3798219-A1 | PHENYL-SUBSTITUTED DIHYDRONAPHTHYRIDINE COMPOUND AND USE THEREOF | Sunshine Lake Pharma Co., Ltd. (CN) | 2021-03-31 | — | — | EP | disclosed |
| US-10829458-B2 | Substituted quinazoline compounds and methods of use thereof | ARAXES PHARMA LLC (US) | 2020-11-10 | — | — | US | disclosed |
| US-10759781-B2 | Substituted guanidine derivatives | UBE INDUSTRIES, LTD. (JP) | 2020-09-01 | — | — | US | disclosed |
| US-20200199121-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20190284144-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | ARAXES PHARMA LLC | 2019-09-19 | — | — | US | disclosed |
| US-20190201412-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | AMGEN INC. (US) | 2019-07-04 | — | — | US | disclosed |
| US-20190152953-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | UBE INDUSTRIES, LTD. (JP) | 2019-05-23 | — | — | US | disclosed |
| WO-2017022861-A1 | SUBSTITUTED GUANIDINE DERIVATIVE | 宇部興産株式会社 | 2017-02-09 | — | — | WO | disclosed |
| WO-2015050471-A1 | CARBAZOLE COMPOUNDS AND METHODS OF USING SAME | OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOST'YU "PANACELA LABS" (RU) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015050472-A1 | FUSED INDOLE COMPOUNDS AND METHODS OF USING SAME | OBSCHESTVO S OGRANICHENNOY OTVETSTVENNOST'YU "PANACELA LABS" (RU) | 2015-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190201412-A1 | COMPOUNDS THAT INHIBIT MCL-1 PROTEIN | MCL1, BCL9, BCL2L1 | NOS3 3598/4885NOS1 2390/4885NOS2 3347/4885 |
| US-11691979-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | NOS3 403/4885NOS1 864/4885NOS2 433/4885 |
| US-20230357254-A1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | IL17A, IL23R, IL15 | NOS3 403/4885NOS1 864/4885NOS2 433/4885 |
| US-20190284144-A1 | SUBSTITUTED QUINAZOLINE COMPOUNDS AND METHODS OF USE THEREOF | KRAS, NRAS, HRAS | NOS3 3294/4885NOS1 2860/4885NOS2 3536/4885 |
| US-10759781-B2 | Substituted guanidine derivatives | GMPS, GUCY1A1, GUCY1A2 | NOS3 729/4885NOS1 416/4885NOS2 440/4885 |
| US-11702422-B2 | Imidazopyridazines as modulators of IL-17 | IL17A, IL23R, IL15 | NOS3 403/4885NOS1 864/4885NOS2 433/4885 |
| US-10829458-B2 | Substituted quinazoline compounds and methods of use thereof | KRAS, NRAS, HRAS | NOS3 3294/4885NOS1 2860/4885NOS2 3536/4885 |
| US-20200199121-A1 | INHIBITORS OF EGFR AND/OR HER2 AND METHODS OF USE | EGFR, ERBB2, ERBB3 | NOS3 3980/4885NOS1 3933/4885NOS2 3738/4885 |
| US-20230373934-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | AR, SHBG, NR5A1 | NOS3 4557/4885NOS1 4763/4885NOS2 4699/4885 |
| US-20190152953-A1 | SUBSTITUTED GUANIDINE DERIVATIVES | GMPS, GUCY1A1, GUCY1A2 | NOS3 729/4885NOS1 416/4885NOS2 440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.